Alder's Breakthrough In Treating Migraines

(RTTNews) - Alder BioPharmaceuticals Inc. revealed that an intravenous injection of its lead clinical candidate ALD403 was found to be validated against migraine attacks, an annoying and recurring headache that can cause nausea and blurred vision. The 300 mg and 100 mg doses found to reduce the average number of migraine by 75 percent in up to 33 percent and 31 percent of patients, respectively. The study has achieved the primary endpoint.

Subsequent to the trial results, the shares of Alder on Nasdaq gapped open in the morning and are currently up 55.50 percent at $26.85.

ALD403 is a monoclonal antibody and targets calcitonine gene related peptide or CGRP. According to Alder, CGRP is a small protein involved in the transmission of pain and heightening of sensitivity in migraine.

Migraine is found to be affecting people of 20 to 50 years of age in their peak productivity and it results in $13 billion loss for U.S. employers each year and loss of 113 million working days.

The study was a double blind, randomized and placebo controlled and patients of high frequency migraine of 5 to 14 days per month were enrolled for the study.